-
1
-
-
84655162706
-
Treatment of HER2-positive breast cancer: Current status and future perspectives
-
Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9(1):16-32.
-
(2012)
Nat Rev Clin Oncol.
, vol.9
, Issue.1
, pp. 16-32
-
-
Arteaga, C.L.1
Sliwkowski, M.X.2
Osborne, C.K.3
-
2
-
-
80053539103
-
Adjuvant trastuzumab in HER2-positive breast cancer
-
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283.
-
(2011)
N Engl J Med.
, vol.365
, Issue.14
, pp. 1273-1283
-
-
Slamon, D.1
Eiermann, W.2
Robert, N.3
-
3
-
-
84855297353
-
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial
-
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.
-
(2012)
Lancet Oncol.
, vol.13
, Issue.1
, pp. 25-32
-
-
Gianni, L.1
Pienkowski, T.2
Im, Y.H.3
-
4
-
-
84862893473
-
Pathological complete response and accelerated drug approval in early breast cancer
-
Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med. 2012;366(26):2438-2441.
-
(2012)
N Engl J Med.
, vol.366
, Issue.26
, pp. 2438-2441
-
-
Prowell, T.M.1
Pazdur, R.2
-
5
-
-
84899465847
-
A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) Abstract S1-04
-
San Antonio, Texas: Cancer Resarch Abstract 73
-
Tolaney SM, Barry WT, Dang CT, et al. A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) Abstract S1-04. In: San Antonio Breast Cancer Symposium. San Antonio, Texas: Cancer Resarch; 2013. Abstract 73.
-
(2013)
San Antonio Breast Cancer Symposium
-
-
Tolaney, S.M.1
Barry, W.T.2
Dang, C.T.3
-
6
-
-
84655169981
-
Practical implications of gene-expressionbased assays for breast oncologists
-
Prat A, Ellis MJ, Perou CM. Practical implications of gene-expressionbased assays for breast oncologists. Nat Rev Clin Oncol. 2012;9(1):48-57.
-
(2012)
Nat Rev Clin Oncol.
, vol.9
, Issue.1
, pp. 48-57
-
-
Prat, A.1
Ellis, M.J.2
Perou, C.M.3
-
7
-
-
84930718892
-
Molecular Features and Survival Outcomes of the Intrinsic Subtypes within HER2-Positive Breast Cancer
-
press
-
Prat A, Carey JA, Adamo B, et al. Molecular Features and Survival Outcomes of the Intrinsic Subtypes within HER2-Positive Breast Cancer. J Natl Cancer Inst. 2014;in press.
-
(2014)
J Natl Cancer Inst.
-
-
Prat, A.1
Carey, J.A.2
Adamo, B.3
-
8
-
-
62449131093
-
Supervised risk predictor of breast cancer based on intrinsic subtypes
-
Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.8
, pp. 1160-1167
-
-
Parker, J.S.1
Mullins, M.2
Cheang, M.C.3
-
9
-
-
84905920752
-
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T-L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC) In: ASCO. Chicago, IL
-
Abstract LBA4
-
Piccart-Gebhart MJ, Holmes AP, Baselga J, et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T-L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC) In: ASCO. Chicago, IL: J Clin Oncol; 2014. Abstract LBA4.
-
(2014)
J Clin Oncol
-
-
Piccart-Gebhart, M.J.1
Holmes, A.P.2
Baselga, J.3
-
10
-
-
0035884620
-
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
-
Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19(18):3808-3816.
-
(2001)
J Clin Oncol.
, vol.19
, Issue.18
, pp. 3808-3816
-
-
Ellis, M.J.1
Coop, A.2
Singh, B.3
-
11
-
-
84859839286
-
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial
-
Cheang MC, Voduc KD, Tu D, et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res. 2012;18(8):2402-2412.
-
(2012)
Clin Cancer Res.
, vol.18
, Issue.8
, pp. 2402-2412
-
-
Cheang, M.C.1
Voduc, K.D.2
Tu, D.3
-
12
-
-
84923179170
-
Gene expression signatures in preand post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). In: ASCO. Chicago, IL
-
Abstract 506
-
Carey LA, Barry WT, Pitcher B, et al. Gene expression signatures in preand post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). In: ASCO. Chicago, IL: J Clin Oncol; 2014. Abstract 506.
-
(2014)
Clin Oncol
-
-
Carey, L.A.1
Barry, W.T.2
Pitcher, B.3
-
13
-
-
84872847361
-
The genomic landscape of breast cancer as a therapeutic roadmap
-
Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov. 2013;3(1):27-34.
-
(2013)
Cancer Discov.
, vol.3
, Issue.1
, pp. 27-34
-
-
Ellis, M.J.1
Perou, C.M.2
-
14
-
-
84896723087
-
Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) Abstact S5-01
-
San Antonio, Texas: Cancer Research Abstract 73
-
Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) Abstact S5-01. In: San Antonio Breast Cancer Symposium. San Antonio, Texas: Cancer Research; 2013. Abstract 73.
-
(2013)
San Antonio Breast Cancer Symposium
-
-
Sikov, W.M.1
Berry, D.A.2
Perou, C.M.3
-
15
-
-
35148885729
-
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
-
Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395-402.
-
(2007)
Cancer Cell.
, vol.12
, Issue.4
, pp. 395-402
-
-
Berns, K.1
Horlings, H.M.2
Hennessy, B.T.3
-
16
-
-
79959268722
-
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031
-
Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342-2349.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.17
, pp. 2342-2349
-
-
Ellis, M.J.1
Suman, V.J.2
Hoog, J.3
-
17
-
-
84861527388
-
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
-
Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346-352.
-
(2012)
Nature
, vol.486
, Issue.7403
, pp. 346-352
-
-
Curtis, C.1
Shah, S.P.2
Chin, S.F.3
|